The statement below IMO is screaming why is not  every single BP in the Diabetis , cardio space not  even at a clinical trial collabation level or smll partnership level to extend the patents??   Sarcastically speaking , either they ( biotech executives) don't know  what apabetalone benefically does or something more nefarious like its still too much of disrupter to their existing drug pipelines. or they hate DM and won't deal with him, I find it funny in the press realease they say  of the upcoming BETONMACE2 trial, DM has been spouting that comment for  5 years now. Is upcoming in DM's mind forward looking  like in 5 or 10 years ..... i guess so  hope is eternal

"Based on data from the Phase 3 trial, BETonMACE, apabetalone treatment reduced the hazard of MACE and hospitalization due to heart failure by 63% (p=0.0002), among patients taking next-generation glucose-lowering drugs, in a post-hoc analysis." .............. As we're told this will conclusively be demonstrated in BOM2 Trial.